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Summary
Objective—Global data on cervical lesion incidence and progression in HIV-positive is essential 
for understanding the natural history of cervical neoplasia and informing screening policy.
Methods—A systematic review was performed summarizing the incidence and progression of 
cervical lesions in HIV-positive women.
Results—Of 5,882 HIV-positive women from 15 studies, incidence ranged from 4.9 to 21.1 cases 
per 100 woman-years for any cervical lesion and 0.4 to 8.8 cases per 100 woman-years for high 
grade cervical lesions. HIV-positive women showed a median 3-fold higher incidence of cervical 
lesions compared to HIV-negative women. Of 1,099 HIV-positive women from 11 studies, 
progression from low to high grade lesions ranged from 1.2 to 26.2 cases per 100 woman-years. 
Both incidence and progression rates increased with lower CD4 counts. The effect of antiretroviral 
therapy on the natural history of cervical neoplasia remains unclear.
Conclusions—HIV-positive women have higher incidence and progression of cervical 
neoplasia. Cervical cancer screening should be integrated into HIV treatment programs.
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Introduction
In 2008, an estimated 33 million people were HIV infected worldwide, with 2.7 million 
newly acquired HIV infections, most of which occurred in less developed countries1. HIV 
prevalence continues to rise due to both the high rate of new infections and the beneficial 
increase in life expectancy from antiretroviral therapy (ART). HIV is increasingly becoming 
a disease of women, with almost 50% of prevalent cases occurring in females1. This trend is 
particularly noticeable in sub-Saharan Africa where females have approximately three times 
the HIV prevalence of males1.
Many resource limited nations that have high HIV prevalence also have high rates of 
cervical cancer because of limitations of screening and treatment. Cervical cancer is caused 
by infection with carcinogenic HPV genotypes2 and HIV infection is strongly associated 
with a higher prevalence, incidence, and persistence of human papillomavirus (HPV) 
infection3–6. Women with HIV have a higher prevalence of cervical squamous epithelial 
lesions (SIL) and invasive cervical cancer7–13. Recognizing this connection, the CDC 
declared invasive cervical cancer as an AIDS-defining illness in 199314. Additionally, 
reducing cervical cancer in HIV-positive women is a primary focus of a joint public-private 
international initiative launched in 2011, the Pink Ribbon Red Ribbon initiative15.
The large number of women living with HIV underscores the need to better understand the 
natural history of cervical precancer and cancer development in this high-risk population. 
While reports have linked HIV-related immunosuppression with an increased incidence of 
cervical precancer lesions and invasive cervical cancer3,16, there is no global review 
compiling data on rates of incidence and progression of cervical neoplasia in HIV-positive 
women. Thus, we systematically reviewed the current literature on cervical precancer and 
cancer among HIV-positive women worldwide and examine important factors related to 
immunosuppression, including CD4+ T-cell count and ART use.
Methods
In order to identify studies related to cervical lesion incidence, a systematic literature search 
was conducted in MEDLINE for all studies indexed through January 31, 2012 with no 
specified start date using the following search terms: (uterine cervical neoplasms (MeSH 
term) OR pap abnormality OR squamous intraepithelial lesions) AND cohort studies (MeSH 
term) limited to AIDS (keyword for HIV-related studies). Articles written in languages other 
than English were translated and reviewed for inclusion criteria. References of identified 
publications were also used to identify additional published articles for review. For cervical 
lesion incidence, studies were included if: i) the study sample included 20 or more HIV-
positive women; ii) a cohort design was used to assess incidence of SIL or greater and/or 
cervical intraepithelial neoplasia (CIN)1 or greater; and iii) study participants had normal 
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cervical screen at baseline. Where possible, incidence rates were split for high grade versus 
low grade SIL and CIN (HSIL/CIN2–3 and LSIL/CIN1, respectively).
Articles reporting on cervical lesion progression were selected from the chosen incidence 
articles as well as through a separate MEDLINE search. The MEDLINE search was 
conducted for all studies indexed by January 12, 2012 using the following search terms: 
uterine cervical neoplasms (MeSH term) AND progression limited to AIDS (which limits 
the search to HIV-specific publications). Studies were included in the progression analysis 
if: i) the study sample included 20 or more HIV-positive women; ii) a cohort design was 
used to estimate progression to SIL or greater and/or CIN1 or greater; and iii) study 
participants had atypical cells of unknown significance (ASCUS), low-grade SIL (LSIL), or 
low-grade CIN (CIN1) diagnosis at baseline.
Incidence and progression rates were reported as stated in the articles or estimated from 
reported number of cases, subjects and median or mean follow-up time. Additionally, study 
cumulative risks of incidence and of progression were reported. Risk ratios were reported as 
stated in the articles or estimated using the ratio of the study cumulative risks. In this review, 
the term ART is broadly used to mean any ART use (monotherapy or greater). However, in 
the tables and results, ART and highly active antiretroviral therapy (HAART) were labeled 
as written in the individual articles with ART typically referring to monotherapy or dual 
therapy and HAART referring to triple therapy or greater. When the study included both 
women using ART and HAART, the term “mixed ART” is applied. When more than one 
article based on the same study population met the selection criteria for inclusion, the article 
with the largest number of women was used, unless multiple articles could contribute to 
separate analyses.
Results
Incidence of cervical lesions
From 451 screened abstracts, our search identified 15 cohort studies presenting data on the 
incidence of cervical neoplasia with observational data on 5882 HIV-positive women in total 
(Table 1). Most studies were conducted in the European Union (N=7; 47%)7,17–22, with 1 
including women from France and French Guiana10, and 1 including women from Europe 
and South Africa23. Three studies were conducted in the United States24–26, 2 were 
conducted solely in Africa27,28, and 1 took place in Thailand29. No studies came from 
Australia, Central America, or Eastern Europe. Study populations were primarily from 
health clinics, sexually transmitted disease clinics, and drug treatment centers. Less than half 
of the studies (N=6, 40%) had both HIV-positive and HIV-negative populations. Median age 
of study participants ranged from 29 to 43, with most studies having a median age in the low 
30s. The number of participants with follow-up data in the included studies ranged from 27 
to 1,931 HIV-positive women; most had 100 or more HIV-positive study participants. Study 
lengths ranged from less than a year to 8 years, with most studies reporting follow-up visits 
every six months. In 2 of the studies, all study participants were receiving HAART21,30. 
Eleven of the studies had a proportion of the participants receiving ART (3 ART, 3 HAART, 
and 5 mixed HAART/ART)7,10,18,19,22–26,28,29, 1 study had no participants receiving ART27, 
and 1 study did not specify ART use20.
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Cervical lesions were identified through cytology in all of the studies, with 8 confirming 
some or all diagnoses with histology. Incidence rates of any SIL for HIV-positive women 
who had normal cytology at study entry ranged from 4.9 to 21.1 cases per 100 women-years 
(Table 1). In all studies that included HIV-negative populations (N=6, 40%), the incidence 
rate of any SIL was greater in HIV-positive than HIV-negative participants, with a median 3-
fold increase in incidence (range 1.5 – 10.0). Incidence rates of LSIL ranged from 2.0 to 
16.2 cases per 100 women years (Table 1 and Figure 1). Rates of HSIL/CIN2–3 for HIV-
positive women varied from 0.4 to 8.8 cases per 100 women-years. Studies with both HIV-
positive and HIV–negative populations showed higher rates of HSIL/CIN2–3 for HIV–
positive participants. As an additional measure, study cumulative incidence of LSIL and of 
HSIL, though not comparable between studies as study length was variable, also consistently 
showed higher risk for HIV-positive participants than for HIV-negative participants within 
the same study.
Incidence stratified by CD4 counts and antiretroviral use
Seven studies included analysis of lesion incidence by CD4 count categories (Table 
2) 7,10,18,19,21,26,27. As the studies varied in length of follow-up, and varied in the 
categorization of CD4 counts, comparisons of cumulative incidence between studies were 
not meaningful. Within study comparisons, however, show that in 6 studies, lower CD4 
count was associated with an increased incidence of abnormal cervical 
cytology7,10,19,21,26,27, although most estimates were not statistically significant. Two 
studies assessed nadir CD4 counts and reported no statistically significant relationship with 
incidence29,31.
Five studies presented risk ratios for SIL incidence by ART use (Table 3)19,22,26,31,32. Of the 
4 studies that reported on HAART use specifically22,26,31,32, 2 studies found a reduced 
incidence and 2 studies found an increased incidence of SIL for users of HAART. However, 
only 1 of these estimates, finding reduced incidence, was statistically significant22. Two 
studies reported on ART use, with one reporting a decrease and 1 reporting an increase in 
incidence of SIL19,26. Again, only one study, finding increased incidence, found this 
association to be statistically significant26.
Progression of low grade lesions
From 219 screened abstracts, our search for cervical lesion progression studies in HIV-
positive women identified 11 cohort studies, including data from 1099 HIV-positive women 
in total (Table 4). Four of the studies were conducted in the USA33–36, 4 in the European 
Union with one including women from France and French Guiana 7,10,37,38, 2 in Africa28,39, 
and 1 in Brazil. No studies came from Asia, Australia, Central America, or Eastern Europe. 
Half of the studies (N=5, 45%) had both HIV-positive and HIV-negative populations. 
Median age of study participants ranged from 27 to 38, with the majority of studies having a 
median age in the low 30s. Eight of the studies reported a proportion of the participants 
receiving ART (2 ART, 1 HAART, and 5 mixed ART/HAART) 7,10,28,33–36,38. In 3 studies 
ART use was not specified37,39,40. In none of the study populations were all participants 
receiving ART. The number of participants ranged from 28 to 242 HIV-positive women, 
with most having fewer than 100 participants. Study lengths ranged from one year to 7 
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years, with the majority reporting follow-up visits every six months. To assess the grade of 
cervical lesions, most studies used cytology, with 6 studies (56%) confirming some or all 
diagnoses with histology.
Cervical lesion progression rates from LSIL/CIN1 to greater than LSIL/CIN1(most 
commonly HSIL/CIN2–3) for HIV-positive women ranged from 1.2 to 26.2 cases per 100 
women-years. Two studies followed women with ASCUS at baseline33,34, finding a rate of 
13.7 cases of SIL per 100 women-years and 3.2 cases of HSIL per 100 women-years. Study 
cumulative risks, though not comparable between studies, were higher for HIV-positive 
participants than for HIV-negative participants in all five studies that included both 
populations10,33,35,37,39.
Progression of lesions stratified by CD4 counts
Three studies reported progression of cervical lesions separated by CD4 count categories 
(Table 5)10,33,37. The cumulative risks of progression in the studies presenting these data 
appeared to show a trend of increased risk of progression with decreasing CD4 count10,37. 
Risk ratios for progression were higher with lower CD4 count33,37, however only 1 of the 
studies reported statistical significance for this association. Nadir CD4 count was not 
evaluated. None of the studies clearly delineated progression risk for ART users versus non-
users.
Discussion
Our comprehensive search identified 15 studies reporting incident cervical lesions and 11 
studies reporting progression of cervical lesions for HIV-positive women. These studies 
showed a wide range of incidence and progression rates for cervical lesions in HIV-positive 
populations. In studies with both HIV-positive and HIV-negative populations, the incidence 
rate of cervical lesions was a median three-fold higher in HIV-positive women as compared 
to HIV-negative study participants. HIV-positive women were also at least twice as likely to 
have cervical lesions that progressed in severity as compared to HIV-negative women. The 
majority of studies showed that lower CD4 counts were associated with increased incidence 
and progression of cervical lesions in HIV-positive women, however, this relationship was 
usually not statistically significant, often due to small sample size per strata of CD4 counts.
The evidence on ART use and cervical lesion incidence was more inconsistent. Though one 
study showed a reduction in incidence with HAART use versus non-HAART use22, most 
studies found no significant difference between HAART/ART use and non-use19,26,31,32. 
Associations may be confounded by the practice of initiating ART use only in patients with 
low CD4 counts or lack comparability due to differences in CD4 count recovery, HIV 
viremia, and follow-up time after ART initiation. Additionally, ART treatment has evolved 
since its introduction so it is important to note that many of the study populations that 
received ART were receiving single or dual drugs as compared to current standard of triple 
drug combinations (HAART) currently in practice. Life expectancy of HIV-positive 
individuals on HAART is also increasing and thus a greater number of HIV-positive women 
may be susceptible to cervical cancer and associated diseases in the future. In addition, an 
important gap in the literature is the effect of HAART use and progression of cervical 
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lesions. Minkoff et al. (2010) found a significant increase in clearance of SILs among 
adherent women on HAART (adjusted odds ratio 2.4; 95% confidence interval 1.1–5.2) as 
compared to pre-HAART32. Two more recent studies, published after the cut off for this 
analysis, also found a reduction in progression or increase in regression for consistent users 
of HAART41,42. The relationship of HAART use and progression may become more defined 
when additional analyses are done in cohorts of women only on HAART and when HAART 
adherence and effectiveness are considered.
As both HIV and HPV are sexually transmitted infections, the increase in cervical lesions 
found in HIV-positive women may be due to shared behavioral risk factors such as high 
number of sexual partners or high risk sexual partners. However, biological mechanisms 
have also been implicated. The increased risk of cervical lesion development and 
progression seen in women with HIV is postulated to be due to both an impaired immune 
system and an increased potential for unregulated cell growth. For example, cervical 
molecular profiles of HIV-positive women show alterations in oncogenic and immunogenic 
protein expression43–45. Additionally, there is evidence linking the HIV-1 transactivator 
protein (Tat) with increased expression of HPV oncogenes and proliferation of HPV-infected 
cells46. Together these data indicate an altered immune response to HPV infection and an 
altered natural history of cervical cancer in HIV-positive women. In alignment with the 
hypothesis that impaired immune function reduces the ability to clear HPV infection, thus 
increasing the probability of developing cervical precancer and cancer, most studies found 
an inverse association between level of immunosuppression, as indicated by CD4 counts, 
and the incidence and progression of cervical lesions7,10,19,21,26,27,33,37.
Our review is limited, however, by the small number of studies reporting rates for cervical 
lesion incidence and progression, making between-study comparisons difficult. Where 
possible, rates were approximated based on median follow-up time. This review identified 
gaps in the literature on incidence and progression of cervical precancer in HIV-positive 
women. Most studies had a median age for study participants in the low 30s; few studies 
reported on older populations. Given the increased life expectancy of HIV-positive women 
due to HAART, assessment of this growing demographic of women 30 years and older is 
needed. Additionally, HIV viral load was not systematically extracted in this analysis due to 
the general lack of consistent data throughout the studies. Also, we did not find studies 
meeting our criteria that addressed the effects of HAART use on progression risk from low-
grade lesions. A recent large study, which was not included in our literature review, reported 
that HAART use reduced the rate of cervical lesion progression from LSIL (rate ratio 0.52 
for HAART users versus ART non-users)41. HAART use has also been associated with a 
reduction in the combined rate for incidence and progression of cervical neoplasia (rate of 
any progression from normal or LSIL baseline), though not always reaching statistical 
significance28,41,47–49. Additionally, evidence shows that HAART use increases the rate of 
regression of precancerous lesions32,50,51.
The compiled research highlights the high risk of cervical precancer development and 
progression in HIV-positive women. This risk appears to be greater in women with reduced 
immune function but more evidence is needed to determine how HAART use modifies risk 
of incidence and progression. Our findings reinforce the importance of screening for cervical 
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lesions in HIV-positive populations, particularly those with lower CD4 counts that are at a 
higher risk for both incident and progressive cervical disease outcomes. Given the healthcare 
resources focused on HIV care, integrating cervical screening with HIV treatment programs 
is essential to reduce untimely death of women from this preventable cancer.
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Incidence rates reported or calculated for LSIL (A) or HSIL (B) in HIV-positive women. 
Rates are reported as cases per 100 woman-years. Solid lines show unweighted mean rate. 
Dotted lines show 95% confidence intervals around the unweighted mean. *This study 
reports CIN2–3.
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